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Background: The role of human papillomavirus (HPV) in
sinonasal inverted papillomas (IPs) is controversial. Deter-
mining the prevalence of HPV infection and its impact on
the molecular biology of these tumors is critical to charac-
terizing its role in the pathogenesis of IPs.
Methods: A total of 112 paraffin-embedded IPs from 90 pa-
tients were studied. A tissue microarray was constructed
and stained for p16, p53, epidermal growth factor recep-
tor (EGFR), and cyclin D1. HPV presence and types were
determined using PGMY 09/11 primers and integration
using HPV 11 detection of integrated papillomavirus se-
quences by ligation-mediated polymerase chain reaction
(DIPS-PCR).
Results: HPV was detected in 11 of 90 (12%) patients. HPV
11 was found in 9 samples. HPV 6 andHPV 27were found in 1
sample each. EGFR staining proportion was higher in HPV-
positive IPs vs HPV-negative specimens (56.2% vs 23.6%;
p = 0.009). Differences in p16, p53, and cyclin D1 staining
were not significant. HPV-positive lesions tend to progress
to malignancy (p = 0.064). Three samples were analyzed
for integration. Viral integration was found in both malig-
nant tumors but not in the precursor IP.
Conclusion: Degradation of p53 and p16/cyclin D1 dys-
regulation are not important mechanisms in low-risk HPV-
related IP. The low prevalence of HPV in this series indi-
cates it is not a main etiological factor for IPs; however,
when present, low-risk HPV may contribute to the biology
of IPs through an increase of EGFRexpression and a predis-
position for malignant progression by integration into the
cellular genome. C© 2015 ARS-AAOA, LLC.
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S inonasal inverted papillomas (IPs) are benign but locallyaggressive tumors.1 With an incidence between 0.74
and 1.5 cases per 100,000 persons per year, IPs account
for 0.4% to 4.7% of all sinonasal neoplasms.2,3 IPs are
reported to have a substantial recurrence rate of up to 32%,
and degenerate into or simultaneously harbor squamous
cell carcinoma (SCC) in 15% of cases.3,4 The pathogenesis
and etiology of IPs is still unclear. Human papillomavirus
(HPV) has been implicated repeatedly in development of
IPs, but the detection rates vary widely in the literature with
a range of 0% to 72% and an average of about 25%.3,5
HPV infection plays an important role in the clinical evo-
lution of IPs. The reported detection rate of HPV is in-
creased in IPs with high-grade dysplasia and carcinoma
when compared to IPs with no dysplasia or mild dyspla-
sia. Similarly, the HPV detection rate is higher in the IPs
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that recur.5–7 HPV types detected in IPs are most com-
monly low-risk types HPV 6/11, and high-risk types HPV
16/18. Of these subtypes, HPV 6/11 are more common
than HPV 16/18, with an overall unadjusted ratio of low-
risk HPV to high-risk HPV of 2.8:1. When dysplasia or
SCC is present, HPV typing reveals a higher proportion of
high-risk types.5,8
The oncogenic mechanisms of high-risk HPV in head and
neck cancer have been extensively studied and described.
The role of these mechanisms in the pathogenesis of IPs
is still not clear. Previous studies have provided evidence
of the presence of HPV 6 E6 and E7 transcripts in IPs.9
E6 has many biological activities that can lead to cellular
transformation. One of themost studiedmechanisms of this
oncoprotein is its capability to cause the ubiquitination of
p53. The ubiquitin-conjugated p53 is exported from the
nucleus and degraded by proteosomes.10,11 A study of IPs
suggests that this E6-mediated mechanism takes place in
these tumors, in that the levels of p53 and p21 are decreased
in IPs with high-riskHPV compared to the IPs without HPV
infection.7 In contrast, in a previous study, we reported
that regardless of the HPV status high expression of p53
correlates with the presence of carcinoma in IPs.12 Because
decreased p53 levels appear to be a hallmark of high-risk
HPV-induced tumors, this study’s results do not concur
with the hypothesis that malignant transformation of IPs is
an HPV-driven event.
HPV is also reported to increase the expression of epider-
mal growth factor receptor (EGFR) by a direct increment in
its transcription, mediated by E6 (Akerman et al.13), or by
recycling of EGFR mediated by E5.14,15 In IPs, increased
expression of EGFR correlates with high-grade dysplasia
and malignancy.16,17
The HPV protein E7 is able to bind to the tumor suppres-
sor protein Rb and decrease its activity. This depressed Rb
activity is independent from its normal regulatory proteins
cyclin D1 and p16. The transcription factor E2F, which is
normally inhibited by Rb, drives expression of genes that
cause cell-cycle progression from G1 to S phase. The nor-
mal feedback inhibitory protein of this pathway p16INK4a
is typically overexpressed in the presence of HPV trans-
forming proteins. Overexpression of p16 has proven to be
a specific and sensitive marker for HPV involvement in
squamous oropharyngeal cancer.18,19 However, in IPs, p16
could not be established as a marker of HPV infection and
low expression of p16 has been correlated with malignancy
in IPs.12,20 The absence of an elevated p16 expression in IPs
harboring cancer does not support a model where high-risk
HPV E7 protein is a driver of malignant transformation.
Recent studies in head and neck cancer have showed
high-risk HPV integration to the cellular genome with
consequent disruption of important cellular regula-
tory pathways.21 Integration of low-risk HPV has also
been implicated in malignant progression of laryngeal
papillomatosis.22 Using the E7/E5 transcript ratio as an
indirect indicator of HPV integration, 1 study suggested
the integration of HPV in IPs with synchronic SCC.23
The purpose of this study is to describe the clinical and
biological role of HPV infection in a group of 90 patients
with IPs. We study the mechanisms of HPV pathogene-
sis in IPs using a detection of integrated papillomavirus
sequences by ligation-mediated polymerase chain reaction
(DIPS-PCR) assay modified for HPV 11 and complement
this data with previously published immunohistochemistry
for p53, p16, EGFR, and cyclin D1.12
Patients and methods
The study was approved by the University of Michigan
Institutional Review Board (IRB). Patients with IPs were
identified by searching the University of Michigan Pathol-
ogy Archive from the year 1996 to 2011. Other types of
sinonasal papillomas were excluded (ie, fungiform and on-
cocytic/cylindrical papillomas). IPs with dysplasia or carci-
noma were included in the study.
P53, p16, EGFR, and cyclin D1
immunohistochemistry
The p53, p16, EGFR, and cyclin D1 immunohistochem-
istry performed on these specimens has been described and
published.12 A tissue microarray (TMA) was constructed,
deparaffinized, and rehydrated. The immunohistochem-
istry staining was then performed. The tumor area stained
was scored as a proportion on a scale of 1 to 4 (grade 1
= <5%; grade 2 = 5% to 20%; grade 3 = 21% to 50%;
grade 4 = >50%). The intensity of staining was also scored
on a scale of 1 to 4 (1 = no staining; 2 = low intensity; 3
= moderate intensity; 4 = high intensity). Tumors with a
staining intensity score 2 or higher were considered to stain
positive for the biomarker.
DNA extraction from paraffin-embedded IPs
A pathologist marked representative areas of tumor in the
paraffin blocks. Cores were taken from the marked areas,
deparaffinized with xylene, and digested with proteinase K.
DNA quantity and quality were corroborated with an ul-
traviolet (UV)–visible light spectrophotometer using a Nan-
oDrop ND-1000 (NanoDrop Technologies, Wilmington,
DE).
HPV detection
The PGMY 09/11 L1 consensus primer set was used to
detect HPV as described.24 The isolated DNA from each
sample was amplified in the presence of 4 mM MgCl2, 200
μM dNTP mix, 0.2 μM PGMY09/11 primer mix, 0.05
μM β-globin primers (PCO4 and GH20), 1× PCR Buffer
II, and 7.5 U of AmpliTaq Gold DNA polymerase (Roche
Molecular Systems, Branchburg, NJ). Amplification was
performed in an Eppendorf Mastercycler Gradient thermal
cycler (Eppendorf Scientific, Hamburg, Germany) at 95°C
for 9 minutes then 40 cycles of 95°C for 1 minute, 55°C for
1 minute, and 72°C for 1 minute. This was followed by a
final extension at 72°C for 5 minutes, and the amplification
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reaction mixtures were stored at 4°C. For the samples that
showed an L1 PCR product, a new PGMY 09/11 PCR re-
action was performed excluding the β-globin primers. The
DNAwas purified using the QIAquick PCR Purification Kit
as described by the manufacturer (Qiagen Sciences, Ger-
mantown, MD) and Sanger sequenced in the University of
Michigan Genomics Core. The sequences were aligned with
known HPV types using the NCBI Basic Local Alignment
Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
All samples were also analyzed with a second sensitive
method, HPV PCR-MassArray, for the detection and iden-
tification of high-risk HPV types as described.25
HPV 11 DIPS-PCR
To determine the physical state and site of integration
of high-risk HPV 16, a DIPS-PCR–based method was
used.26–28 We modified this method and designed a new
set of primers that will cover the entire low-risk HPV 11
genome (Table 1, Fig. 1). The genomic DNA (800 ng) was
digested using 20 units of Taqα1 (New England Biolabs,
Ipswich, MA) in a volume of 20 μL at 65°C overnight
in an Eppendorf Mastercycler Gradient thermal cycler.
The reaction was heat-inactivated at 80°C for 20 min-
utes. A double-stranded annealed adapter was then lig-
ated to the digested DNA. The adapter consists of a long
strand (5′-gggccatcagtcagcagtcgtagccggatccagacttacacgttg-
3′) and a short strand (5′-PO4-cgcaacgtgtaagtctg-NH2-3′).
The ligation was performed using 3 units of T4 DNA
Ligase (Promega Corporation, WI), 50 pmol annealed
adapter, and the digested DNA in a 20-μL reaction at
14°C overnight. The product was then diluted to 40 μL.
FIGURE 1. Position of Taqα1 restriction sites and DIPS-PCR primers on
HPV 11 genome. Upstream (reverse) primers are indicated by gray arrow-
heads labeled R1 to R5. Downstream (forward) primers are indicated by
black arrowheads labeled F1 to F6. Taqα1 restriction sites are indicated
by dashed lines. DIPS-PCR = detection of integrated papillomavirus se-
quences by ligation-mediated polymerase chain reaction; HPV = human
papillomavirus.
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A first linear PCR reaction was performed using 2 μL of
the previously digested and ligated DNA, 1× PCR buffer,
1.5 mM MgCl2, 200 μM dNTP mix, 0.2 μM viral lin-
ear primer, and 1 unit Platinum Taq DNA Polymerase
(Invitrogen, Life Technologies, NY) in a total volume of
25 μL. The reaction parameters were an initial denatura-
tion at 96°C for 2 minutes, then 40 cycles of 96°C denat-
uration for 30 seconds, 62°C primer annealing for 30 sec-
onds, and 72°C primer extension for 3 minutes followed
by a final 72°C extension for 7 minutes. For the second
exponential PCR reaction we used 2 μL of the first lin-
ear PCR product, 1× PCR buffer, 1.5 mM MgCl2, 200
μM dNTP mix, 0.4 μM viral exponential primer, 0.4 μM
adapter-specific primer (5′-ggccatcagtcagcagtcgtag-3′) and
1 unit Platinum Taq DNA Polymerase in a total volume of
25 μL. The reaction parameters were an initial denatura-
tion at 96°C for 2 minutes, then 30 cycles of 96°C denat-
uration of 30 seconds, 62°C primer annealing for 30 sec-
onds, and 72°C primer extension for 3 minutes, followed
by a final 72°C extension for 7 minutes. The PCR prod-
ucts were analyzed using electrophoresis in a 2% agarose
gel. The resulting bands were cut from the gel and puri-
fied using the QIAquick Gel Extraction Kit as described
by manufacturer (QIAGEN Sciences, MD). The purified
DNA was sequenced, and the integration sequences were
detected using theNCBI Basic Local Alignment Search Tool
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Statistical analysis
Mean percentage staining by tumor surface area for HPV-
positive and HPV-negative IPs were compared using 2-
tailed t test. Staining proportions were compared using a
2-tailed Z test for proportions. All p values <0.05 were
considered to be statistically significant, and values between
0.05 and 0.10 as indicating a statistical trend.
Results
A total of 162 paraffin-embedded specimens from 147 pa-
tients were collected and studied. Twenty-two specimens
(13.6%) harbored carcinoma. One hundred and eleven
(111) patients (75.5%) were male. The population char-
acteristics have been described.12,29
HPV incidence and types
DNA was successfully extracted for analysis from 112/162
IP samples corresponding to 90 patients. HPV detection
was carried out using the PGMY PCR-based detection
method.24 Coamplification of β-globin was used as a
reaction-positive control. Eleven (12.2%) of the 90 patient
tumors studied were HPV-positive (Table 2.). One patient
with an HPV-positive tumor had 2 specimens collected 1
year apart. Both samples were positive for the same HPV
type, and the second sample contained SCC. From the 11
HPV-positive tumors, 9 contained HPV 11, one contained
HPV 6, and one containedHPV 27. There were no high-risk
TABLE 2. HPV detection in patients with sinonasal inverted
papillomas
HPV type Proportion
HPV negative 79/90 (89%)
HPV 11 9/90 (10%)
HPV 6 1/90 (1.1%)
HPV 27 1/90 (1.1%)
HPV = human papillomavirus.
HPV types detected in this patient cohort as assessed by the
PGMY L1 assay and confirmed by HPV PCR-MassArray.
HPV status and expression of EGFR, p16, p53, and
cyclin D1 immunohistochemistry
The HPV status was compared to p53, p16, EGFR, and cy-
clin D1 protein levels (Tables 3 and 4). Immunohistochem-
istry data was available for 77 tumors, 8 HPV-positive,
and 69 HPV-negative. HPV-infected IPs stained for EGFR
in 87.5% (7/8) tumors, whereas only 58% (40/69) of HPV-
negative IPs stained for EGFR. This difference was not sta-
tistically significant (p = 0.11). However, when the mean
percentage area of the tumor stained for EGFR was con-
sidered, HPV-positive tumors had increased staining com-
pared to theHPV-negative tumors, with a stainedmean per-
centage area of 56.2% vs 23.6%, respectively (p = 0.009).
TABLE 3. Average percentage area stained for p16, EGFR,
p53, and Cyclin D1 for HPV-positive vs HPV-negative IPs
HPV-positive HPV-negative pa
p16 (% average) 11.67 10.27 0.858
EGFR (% average) 56.25 23.65 0.009
p53 (% average) 11.04 8.49 0.612
Cyclin D1 (% average) 17.08 17.23 0.983
aBold p values are significant.
EGFR = epidermal growth factor receptor; HPV = human papillomavirus; IP =
inverted papilloma.
TABLE 4. Biomarker staining for HPV-positive vs
HPV-negative IPs
HPV-positive HPV-negative p
p16-positive 4/8 (50%) 49/69 (71%) 0.22
EGFR-positive 7/8 (87%) 40/69 (58%) 0.11
p53-positive 5/8 (63%) 35/69 (51%) 0.52
Cyclin D1-positive 6/8 (75%) 57/71 (80%) 0.72
EGFR = epidermal growth factor receptor; HPV = human papillomavirus; IP =
inverted papilloma.
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Positive p16 immunohistochemistry was observed in
50% (4/8) of the HPV-infected IPs vs 71% (49/69) of HPV-
negative IPs although the difference was not significant (p=
0.22). The tumor mean percentage area stained for p16 was
11.7% vs 10.3% for the HPV-positive and HPV-negative
tumor, respectively (p = 0.858).
Positive staining for p53 was present in 62.5% (5/8) of
HPV-positive specimens vs 50.7% (35/69) of HPV-negative
samples (p = 0.52). The mean area stained for p53 was
11% for HPV-infected specimens and 8.5% for HPV-free
specimens (p = 0.612).
Cyclin D1 immunohistochemistry was positive in 75%
(6/8) of HPV-infected and 80% (57/71) of HPV-negative
samples (p = 0.72). Tumor mean percentage areas were
17.08% and 17.23% for HPV-positive and HPV-negative
samples, respectively (p = 0.983).
HPV in cancer progression and papilloma
recurrence
Progression of IPs to SCC occurred in 36.36% (4/11) HPV-
positive patients, and 14.1% (11/78)HPV-negative patients
(p = 0.064). All HPV-positive patients who presented with
SCC had HPV 11 infection. Also, IPs recurred in 63.64%
(7/11) of HPV-positive vs 45.33% (34/75) of HPV-negative
lesions (p = 0.256).
Integration of HPV 11 in inverted papillomas that
progressed to SCC
From the HPV 11–positive specimens, only 3 had sufficient
DNA forHPV 11DIPS-PCR analysis. Two of the specimens
were from the same patient. The first specimen was an IP,
and 1 year later a specimen containing SCC was obtained
from this patient. The specimen with SCC showed that
HPV 11 had 1 integration site in an intergenic region of
chromosome 5q31. TheHPV 11 insertional breakpoint was
found in L1. The IP obtained 1 year earlier from the same
patient did not show any HPV integration events.
The third specimen analyzed with HPV 11 DIPS-PCR is
a SCC that contained 3 integration events. The integrations
were found in intergenic regions of chromosomes 18q11.1,
5p13.2, and 2p22.1. TheHPV integration breakpoints were
in E6, L1, and L1, respectively.
Discussion
Many etiological agents have been proposed for IPs. HPV
has been proposed as the main etiological factor. How-
ever, in our dataset only a low proportion of IPs, 11 in
90 (12.2%) of our patients, harbor HPV in their lesions.
A recent meta-analysis reported that HPV has been found
in 25% of IPs, with high variability between studies.5 The
lowHPV presence suggests that it is only 1 of the etiological
agents for IPs.
Interestingly, we did not find any high-risk HPVs in the
IPs studied. We used 2 robust assays, 1 based on consen-
sus L1 PCR primers PGMY 09/11 (Gravitt et al.24) and
the HPV multiplex PCR MassArray analysis based on the
viral E6 region.25 Even without the presence of high-risk
HPVs, we noted a trend for low-risk HPV-positive samples
to have a greater proclivity for malignant progression to
invasive squamous carcinoma than HPV-negative samples
IPs. However, this trend was not statistically significant.
This observed tendency to progression was further studied
in a meta-analysis and proved that HPV-positive samples
progress more frequently than HPV-negative IPs. They also
found that HPV-positive IPs have a higher recurrence rate
than the HPV-negative tumors, a correlation that was not
found in our study. This discrepancy could be caused by
our lower statistical power due to our low number of HPV-
positive cases, or by a difference in the biological activity of
high-risk HPV vs low-risk HPV. In contrast to our study,
in the cited meta-analysis high-risk HPV 16/18 were de-
tected in 3.5% (0% to 33.3%) IPs with no or low-grade
dysplasia and 33.8% (0% to 100%) IPs with SCC.5 The
role of low-risk HPV as a prognostic marker has not been
confirmed.
The variability of HPV detection between studies can be
a reflection of different patient characteristics and may also
include varying levels of HPV detection expertise. Sample
sets that include a higher number of dysplastic and malig-
nant lesions and higher numbers of recurrent cases are more
likely to have higher HPV incidence.5,30 Laboratories with
greater experience with HPV detection and strong quality
control measures may have more accurate HPV detection
rates and lower false-positive rates.31–33
The oncogenic mechanisms of HPV have been studied ex-
tensively. Most high-risk HPV-induced cancers are driven
by the viral oncogenes. HPV-positive tumor cell lines are
dependent on E6 and E7 expression for proliferation and
survival.34–36 Whereas most attention has been given to
these HPV-mediated effects on the p53 and pRb pathways,
this study’s results indicate the importance of HPV-induced
upregulation of EGFR expression.13–15 EGFR mean per-
centage area staining was the only biomarker that was sig-
nificantly increased in our low-risk HPV-positive set com-
pared to the HPV-negative cases. Cyclin D1, p16, and p53
expression showed no difference between the 2 groups.
These results provide a rationale to test EGFR inhibitors
for the treatment of low-risk HPV-positive IPs. The Radio-
therapy plus Cetuximab multicenter study of locoregion-
ally advanced head and neck cancer reported by Bonner et
al.37 revealed that overall survival was only modestly in-
creased in the radiotherapy plus cetuximab arm over radia-
tion alone. However, in a subsequent follow-up at 5 years,
the survival advantage for the cetuximab arm became sig-
nificant. In subgroup analysis, male patients less than 65
years old, treated in the United States with T1-3, N1-N3
oropharynx cancer exhibited the greatest benefit from the
addition of cetuximab to the treatment.37 This effect could
be attributed to the presence of HPV, considering that it has
been established that HPV is now the main etiologic agent
for oropharynx cancer,38 whereas in head and neck can-
cers at other sites the role of HPV is not as significant.25,39
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Furthermore, Kies et al.40 treated oropharynx cancer with
paclitaxel and carboplatin with and without cetuximab and
found that survival was better for the HPV-positive patients
in the cetuximab group. Thus, it is conceivable that there
may be a role for anti-EGFR treatment in the management
of HPV-related sinonasal tumors.
Recent studies indicate that integration of high-risk HPV
in human genomic DNA from SCC can disrupt important
cell regulatory genes.21 Here we designed a DIPS-PCR as-
say modified to detect the integration of low-risk HPV 11
into human genomic DNA. Interestingly, we found that
all of the low-risk HPV 11 integrations were in intergenic
DNA regions and did not directly alter the sequence of
any gene. This is in contrast to gene disruption by intra-
genic high-risk HPV integration as a secondary factor in
oncogenesis.21 However, Schmitz et al.41 observed that in
a large number of cervical carcinomas, intergenic integra-
tion also frequently occurs in the vicinity of microRNAs,
which could also alter host cell gene expression and foster
malignant progression. In their work, Schmitz et al.41 noted
that the integration process of high-risk HPVs was directed
by cellular homologies with the viral E5 and L2 sequences.
These homologies targeted 9 genes that were commonly
disrupted.41 In this study we found that the low-risk HPV
11 was frequently integrated in the L1 sequence. This find-
ing suggests that integration of HPV 11 is also a targeted
process, but more studies are necessary to confirm this.
In 1 subject, an initial IP sample and a second sample
that was obtained when the lesion progressed to SCC were
available for evaluation. There was no HPV 11 integration
present in the IP sample, although an HPV 11 intergenic
integration was present in the SCC sample 1 year later.
Huebbers et al.22 reported similar findings in a case of a
young woman with HPV 6–positive recurrent respiratory
papilloma that progressed to SCC. HPV integration was
not found in 2 respiratory papilloma specimens but in the
later SCC sample from this patient, HPV 6 was integrated
into aldo-keto reductase 1C3, resulting in gene disruption
and loss of function.22 These results indicate that HPV in-
tegration occurs concurrently with malignant transforma-
tion, but it is still unclear whether the viral integration is a
driver of malignancy or a consequence of genomic instabil-
ity caused by HPV-independent mechanisms.
Conclusion
The low frequency of HPV in IPs in this series suggests that
this virus is not amajor etiological agent for this disease.We
identified a trend to progression to carcinoma in the pres-
ence of HPV, an observation that has been confirmed in a
recent meta-analysis.4 EGFRwas the only biomarker tested
that was overexpressed in low-risk HPV positive samples,
suggesting that anti-EGFR therapy could have a role in re-
ducing risk of progression inHPV-positive IPs. Intriguingly,
our results suggest that integration of HPV into the cellular
genomic DNA occurs with malignant transformation, but
this requires further study. It is unclear if viral integration
is the cause or a consequence of malignancy.
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